Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 359, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.jneuroim.2021.577676
Keywords
Multiple sclerosis; Ublituximab; B cell; T cell; CD20; Regulatory T cell
Categories
Funding
- TG Therapeutics, Inc.
Ask authors/readers for more resources
B cell depletion therapy has shown to be beneficial in multiple sclerosis, possibly by favorably altering the proportions of T cell subsets.
B cell depletion therapy has been shown to be beneficial in multiple sclerosis (MS). However, the mechanism by which B cell depletion mediates its beneficial effects in MS is still unclear. To better understand how B cell depletion may benefit patients with a disease previously thought to be primarily mediated by CD4 T cells, immune profiles were monitored in 48 patients in a phase II trial of ublituximab, a glycoengineered CD20 monoclonal antibody, at 18 time points over a year. As we previously described there was a significant shift in the percentages of T cells, NK cells, and myeloid cells following the initial dose of ublituximab, but this shift normalized within a week and these populations remained stable for the duration of the study. However, T cell subsets changed with an increase in the percentage of naive CD4 and CD8 T cells and a decline in memory T cells. Importantly, the percentage of Th1 and CD4+GM-CSF+ T cells decreased, while the percentage of Tregs continued to increase over the year. Ublituximab not only depleted CD20+ B cells, but also CD20+ T cells. The favorable changes in the T cell subsets may contribute to the beneficial effects of B cell depletion therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available